|
|||||
|
Latest Insider Trading | Top Insider Trading Recent Week | Top 10% Owner Trading Recent Week | Filter |
Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
MRNA | Mock James M | Chief Financial Officer | Nov 29 '24 | Sale | 42.79 | 1,420 | 60,761 | 11,066 | Dec 02 04:26 PM |
MRNA | Mock James M | Officer | Nov 29 '24 | Proposed Sale | 42.79 | 1,420 | 60,761 | Nov 29 03:35 PM | |
MRNA | Mock James M | Chief Financial Officer | Oct 07 '24 | Sale | 60.12 | 715 | 42,986 | 9,505 | Oct 08 04:19 PM |
MRNA | Mock James M | Chief Financial Officer | Aug 29 '24 | Sale | 78.03 | 162 | 12,640 | 8,767 | Aug 30 04:37 PM |
MRNA | Mock James M | Chief Financial Officer | Aug 28 '24 | Sale | 79.39 | 1,321 | 104,881 | 8,600 | Aug 29 04:45 PM |
MRNA | Mock James M | Officer | Aug 29 '24 | Proposed Sale | 78.03 | 162 | 12,640 | Aug 29 03:43 PM | |
MRNA | Mock James M | Officer | Aug 28 '24 | Proposed Sale | 79.39 | 1,321 | 104,881 | Aug 28 04:47 PM | |
MRNA | Mock James M | Chief Financial Officer | Jul 08 '24 | Sale | 118.24 | 689 | 81,465 | 7,269 | Jul 09 04:34 PM |
MRNA | Mock James M | Chief Financial Officer | Jun 03 '24 | Sale | 140.72 | 691 | 97,237 | 6,506 | Jun 04 05:27 PM |
MRNA | Mock James M | Chief Financial Officer | May 29 '24 | Sale | 144.50 | 183 | 26,444 | 5,871 | May 30 04:36 PM |
MRNA | Mock James M | Chief Financial Officer | May 28 '24 | Sale | 162.47 | 648 | 105,283 | 5,726 | May 29 04:16 PM |
MRNA | Mock James M | Chief Financial Officer | Apr 08 '24 | Sale | 101.93 | 705 | 71,859 | 5,048 | Apr 09 04:09 PM |
MRNA | Mock James M | Chief Financial Officer | Feb 29 '24 | Sale | 94.57 | 647 | 61,188 | 4,300 | Mar 01 05:33 PM |
MRNA | Mock James M | Chief Financial Officer | Jan 08 '24 | Sale | 109.75 | 772 | 84,731 | 3,632 | Jan 09 04:08 PM |
MRNA | Mock James M | Chief Financial Officer | Oct 06 '23 | Sale | 102.50 | 2,858 | 292,953 | 2,952 | Oct 10 04:51 PM |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite